Wspolczesna Onkologia-Contemporary Oncology最新文献

{"title":"Interleukins as a potential link between obstructive sleep apnea and renal cell carcinoma.","authors":"Katarzyna Stańska-Kowalik, Kamila Maliszewska-Olejniczak, Michał Fiedorowicz, Anna M Czarnecka, Wojciech Kukwa","doi":"10.5114/wo.2025.151584","DOIUrl":"10.5114/wo.2025.151584","url":null,"abstract":"<p><strong>Introduction: </strong>Intermittent hypoxia and the inflammatory processes occur in both obstructive sleep apnea (OSA) and renal cell carcinoma (RCC). In recent years, multiple studies have shown a dose-dependent effect of OSA on the risk and prognosis of RCC. However, the pathogenesis of this process is still unknown. This study aimed to review the literature and identify the similarities in cytokine profiles of patients with OSA and RCC.</p><p><strong>Material and methods: </strong>We included articles in English assessing cytokine levels in pediatric and adult patients with OSA and in patients with RCC. The exclusion criteria were animal and <i>in vitro</i> studies. The PubMed database was searched for articles.</p><p><strong>Results: </strong>After analyzing the search results, 66 articles were selected. Twenty different interleukins were studied in OSA research. Most RCC pro-cancerogenic cytokines (IL-1, IL-4, IL-6, IL-8, IL-17, IL-18, IL-23, IL-33) had higher levels in OSA patients than in controls.</p><p><strong>Conclusions: </strong>This review emphasizes similarities in a spectrum of cytokines in OSA and RCC patients, with significantly elevated levels of RCC pro-cancerogenic interleukins in OSA patients. This may suggest a possible link between untreated OSA and the prognosis of RCC. Also, the treatment of OSA with continuous positive airway pressure led to a decrease in pro-cancerogenic cytokines, which could have important therapeutic implications in OSA-positive patients treated for RCC.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"131-149"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative systemic inflammatory biomarkers can improve recurrence prediction of non-muscle invasive bladder cancer after endoscopic resection - a prospective observational study.","authors":"Klaudia Bardowska, Wojciech Krajewski, Anna Kołodziej, Katarzyna Kościelska-Kasprzak, Dorota Bartoszek, Marcelina Żabińska, Joanna Chorbińska, Tomasz Królicki, Magdalena Krajewska, Tomasz Szydełko, Dorota Kamińska","doi":"10.5114/wo.2025.151064","DOIUrl":"10.5114/wo.2025.151064","url":null,"abstract":"<p><strong>Introduction: </strong>Non-muscle invasive bladder cancer (NMIBC) is one of the most commonly diagnosed urogenital types of cancer with a relatively favourable prognosis. Cystoscopy stands as the most significant diagnostic and monitoring procedure, however more accessible methods are needed for diagnosis and follow-up.</p><p><strong>Material and methods: </strong>A total of 285 pa-- tients with NMIBC were enrolled in this prospective study. Complete blood count (CBC) biomarkers and nutritional risk scores were evaluated for predicting cancer recurrence or progression after radical transurethral resection of bladder tumour (TURB). Additionally, the correlation between CBC biomarkers and European Organisation for Research and Treatment of Cancer (EORTC) risk scores was performed. A final study group with complete follow-up and dataset, comprised of 183.</p><p><strong>Results: </strong>After a 3-month follow-up period, 104 subjects experienced cancer recurrence or progression. A group of 79 patients were tumour free. The neutrophil-to-lymphocyte ratio (NLR) showed the highest area under the curve of 0.618 (95% CI: 0.536-0.699) with <i>p</i> = 0.0047, for discrimination of the study outcomes. None of nutritional risk scores has predicted disease progression or recurrence. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio and derived NLR enhanced the diagnostic performance for EORTC recurrence and progression points.</p><p><strong>Conclusions: </strong>Complete blood count biomarkers can predict recurrence or progression of NMIBC after TURB, yet nutritional risk scores have demonstrated inadequate predictive value. Complete blood count biomarkers increase prognostic properties of EORTC risk score.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"188-194"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of oligometastatic non-small cell lung cancer with radiotherapy - single-centre experience.","authors":"Artur Bandura, Paweł Tran Dinh, Anna Wrona, Krzysztof Konopa, Rafał Dziadziuszko","doi":"10.5114/wo.2025.151117","DOIUrl":"10.5114/wo.2025.151117","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer is one of the most common malignancies in the world. Many attempts have been made to increase survival of this devastating disease, including the addition of local therapies in oligometastatic non-small cell lung cancer (OMD NSCLC). Oligometastatic disease is an intermediate state between a local and widely disseminated disease. The aim of the study was to assess the efficacy of stereotactic radiation therapy (SRT) in treatment of OMD NSCLC and to evaluate prognostic factors for survival.</p><p><strong>Material and methods: </strong>Medical records of 127 consecutive patients with OMD NSCLC who underwent SRT in University Clinical Centre in Gdańsk, Poland between 2016 and 2022 were obtained and clinical data were analysed for toxicity and efficacy.</p><p><strong>Results: </strong>There were 64.6% of patients with adenocarcinoma, 25.2% with squamous-cell carcinoma and 10.2% with other histological subtypes. Mean age was 66.9 years. Treatment was well tolerated in the majority of patients. Median progression-free survival (PFS) for synchronous OMD (sOMD) and metachronous OMD (mOMD) was 11.1 months and 14.4 months, respectively (<i>p</i> = 0.61). Median PFS for oligoprogression was 5.43 months. Median overall survival for sOMD and mOMD was 24.5 months and 36.8 months, respectively (<i>p</i> = 0.11). The most important prognostic factors were the number of metastases and performance status.</p><p><strong>Conclusions: </strong>Radical treatment in OMD NSCLC should be judicious and reserved for selected patients. Stereotactic radiation therapy is an important tool in the management of OMD NSCLC.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"179-187"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.","authors":"Oktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, Kamil Wiśniewski, Joanna Drozd-Sokołowska, Marta Morawska, Urszula Gosik, Dariusz Woszczyk, Agata Ogłoza, Kamil Wdowiak, Ewa Paszkiewicz-Kozik, Ewa Wąsik-Szczepanek, Mirosław Markiewicz, Magdalena Zawartko, Anna Kokoć, Anna Szumera-Ciećkiewicz, Monika Prochorec-Sobieszek, Dorota Jesionek-Kupnicka, Marcin Braun, Beata Gierej, Tadeusz Robak, Ewa Lech-Marańda, Bartosz Puła","doi":"10.5114/wo.2025.149235","DOIUrl":"https://doi.org/10.5114/wo.2025.149235","url":null,"abstract":"<p><strong>Introduction: </strong>Accelerated chronic lymphocytic leukemia (A-CLL) is a rare histological variant of CLL, which is associated with an aggressive clinical presentation and worse prognosis. The aim was to study the characteristics and treatment outcomes of A-CLL patients.</p><p><strong>Material and methods: </strong>The retrospective analysis included 106 A-CLL patients treated in Poland between 2013 and 2023.</p><p><strong>Results: </strong>Median overall survival (OS) for treatment-naive A-CLL was 6.05 years (95% CI: 4.7-NA) and median progression-free survival (PFS) was 5.66 years (95% CI: 4.05-6.34). Factors associated with worse PFS were: Eastern Cooperative Oncology Group > 2 (<i>p</i> < 0.0001) and del17p (<i>p</i> = 0.002). In the whole group, fludarabine-based regimens improved OS (<i>p</i> = 0.002) and PFS (<i>p</i> = 0.002). This therapy proved superior to R-CHOP-like protocols for both OS (<i>p</i> = 0.002) and PFS (<i>p</i> = 0.004). The difference in survival between fludarabine-based regimens and targeted therapy was not significant. However, the group of patients treated with new therapies was very heterogeneous. Fludarabine (p = 0.004) or targeted therapy (<i>p</i> = 0.02) in any line of treatment during acceleration was associated with a reduced risk of death.</p><p><strong>Conclusions: </strong>This study represents one of the largest datasets of A-CLL patients and shows its poorer prognosis compared to typical CLL. Chronic lymphocytic leukemia directed therapy should be considered as a treatment modality of choice for A-CLL. R-CHOP protocols are less effective.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"28-35"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microglandular adenosis associated with triple-negative invasive breast carcinoma - a case report and literature review.","authors":"Aleksandra Zielinska, Mateusz Matczak, Laura Stachura, Robert Kubiak, Tomasz Michalski, Hanna Romańska, Marcin Braun","doi":"10.5114/wo.2025.150081","DOIUrl":"10.5114/wo.2025.150081","url":null,"abstract":"<p><p>Microglandular adenosis (MGA) is a rare benign breast condition characterized by disorganized small glands composed of epithelial cells without myoepithelial components. Microglandular adenosis can coexist with invasive breast cancer (IBC), particularly the triple-negative (TN) subtype. Emerging evidence suggests MGA may be a precursor to IBC, supported by shared morphological and molecular features. We present the case of a 66-year-old woman with a palpable mass in the left breast. Initial mammography and biopsy suggested malignancy. The patient underwent breast-conserving surgery with resection of the sentinel lymph node. Histopathological analysis confirmed triple-negative, basal-like invasive breast carcinoma with focal salivary gland-type carcinoma differentiation, likely arising from an MGA-like component. The patient subsequently received adjuvant chemotherapy, and no recurrence was observed after a 30-month follow-up. This case underscores the importance of recognizing MGA as a potential precursor to invasive breast carcinoma, particularly the TN subtype. Increased awareness and the use of comprehensive diagnostic methods are essential for improving patient outcomes and managing the risks associated with MGA, especially in cases that may progress to more aggressive forms of cancer.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"210-214"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer.","authors":"Agata Adamczuk-Nurzyńska, Paweł Nurzyński, Melania Brzozowska, Maciej Jewczak, Andrzej Śliwczyński","doi":"10.5114/wo.2025.150080","DOIUrl":"10.5114/wo.2025.150080","url":null,"abstract":"<p><strong>Introduction: </strong>In 2020 in Poland a total of 3 589 people had pancreatic cancer (PC). Only 20% of patients were diagnosed with surgical disease. New therapeutic options that demonstrate statistically significant improvements in overall survival (OS) and progression-free survival (PFS) are still being sought. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice.</p><p><strong>Material and methods: </strong>The aim of the clinical study was a retrospective analysis of the medical history of 182 patients with the diagnosis of metastatic pancreatic cancer (mPC), who were treated with combination treatment of nab-paclitaxel with gemcitabine (GEM-NAB) between February 2017 and September 2023. Our study also aimed to identify important population-based predictors for survival in patients diagnosed with mPC.</p><p><strong>Results: </strong>The median age was 66 years (range 37-84 years). Median OS was 9.2 months (95% CI: 8.3-10.03), and median PFS was 5.47 months (95% CI: 4.83-6.1); 26 patients achieved either a partial or complete response (overall response rate 14%). GEM-NAB was well tolerated. The most common adverse events were alopecia, fatigue, neutropenia, anemia, and peripheral neuropathy. This study identified specific clinical and laboratory parameters (neutrophil to lymphocyte ratio, antigen Ca 19.9, mechanical jaundice, peripheral neuropathy and 2^nd and 3^rd lines of treatment) as independent prognostic factors.</p><p><strong>Conclusions: </strong>Our results confirm the efficacy and tolerability of GEM-NAB as standard first-line treatment in patients with mPC. Among the factors having the greatest impact on OS was the 3^rd line of treatment, and for PFS the presence of peripheral neuropathy.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"171-178"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene.","authors":"Yosuke Maezawa, Manato Taguchi, Takeshi Kawakami, Toshihide Inui, Shinichiro Okauchi, Takeshi Numata, Toshihiro Shiozawa, Kunihiko Miyazaki, Ryota Nakamura, Kesato Iguchi, Takeo Endo, Tohru Sakamoto, Hiroaki Satoh, Nobuyuki Hizawa","doi":"10.5114/wo.2025.148231","DOIUrl":"https://doi.org/10.5114/wo.2025.148231","url":null,"abstract":"<p><strong>Introduction: </strong>It is widely accepted that anaplastic lymphoma kinase (ALK) fusion gene-positive non-small cell lung cancer (NSCLC) patients are more likely to be in their 50s, female, and non-smoking. This seems to be due to the background of patients involved in clinical trials of ALK-tyrosine kinase inhibitors. However, in daily clinical practice, it is not uncommon to encounter elderly ALK-positive NSCLC patients with a smoking history. In light of this background, we conducted a survey to clarify the clinical backgrounds of ALK-positive patients with NSCLC, particularly regarding age and smoking.</p><p><strong>Material and methods: </strong>A retrospective medical chart survey of patients with ALK-positive NSCLC diagnosed in 2012 to 2024 in our six institutes was conducted.</p><p><strong>Results: </strong>During the study period, 140 pa-- tients were diagnosed with ALK-positive NSCLC, of which 90 (64.3%) were women. The median age of all 140 pa-- tients was 63 years (range, 26-84 years). Among these 140 patients, 38.6% had a history of smoking. There was a significant difference in the distribution of smokers by sex and age.</p><p><strong>Conclusions: </strong>Even among NSCLC patients who are elderly or have a history of smoking, there may be some who miss out on the best possible treatment by exclusion from ALK testing. Discussions considering the efficiency and cost of testing are needed, and it is essential to collect and reanalyse as much information as possible about the clinical characteristics of ALK-positive NSCLC patients.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"93-98"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food interactions with tyrosine kinase inhibitors used to treat advanced renal cell carcinoma.","authors":"Agata Sałek-Zań, Mirosława Püsküllüoğlu, Karolina Syrek-Kaplita, Tomasz Banaś","doi":"10.5114/wo.2025.148229","DOIUrl":"https://doi.org/10.5114/wo.2025.148229","url":null,"abstract":"<p><p>Renal cancer accounts for approximately 4.4% of all malignant tumors worldwide. In the case of tumors limited to the kidney, the primary method of treatment is surgery. For advanced renal cell carcinoma (RCC), one of the treatment methods is targeted therapy aimed at molecular targets via tyrosine kinase inhibitors (TKIs). These drugs are administered orally, significantly improving the comfort of patients. However, for a drug administered in oral form to produce the intended effect in the body, it must undergo many transformations during which it interacts with various chemical compounds. These include other medications taken by the patient and those derived from food. As a result of these interactions, at each stage of the drug's transformation, there may be interactions between that drug and these substances. Information about possible drug-drug interactions is widely available. In contrast, knowledge about drug-food interactions is a relatively new area of medical research. It has been demonstrated that these interactions can affect not only the increased toxicity of the therapy but also its effectiveness. This study reviews the possible interactions of popular food products with TKIs used in RCC treatment, at different stages of drug metabolism, and the possible mechanisms of these interactions.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"1-10"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer, malnutrition and inflammatory biomarkers. Why do some cancer patients lose more weight than others?","authors":"Aleksandra Kapała, Katarzyna Różycka, Ewelina Grochowska, Aleksandra Gazi, Emilia Motacka, Marcin Folwarski","doi":"10.5114/wo.2025.147939","DOIUrl":"https://doi.org/10.5114/wo.2025.147939","url":null,"abstract":"<p><strong>Introduction: </strong>Malnutrition is highly prevalent in cancer patients, significantly influencing their clinical outcomes and prognosis. The study was conducted to investigate the association between inflammatory biomarkers, nutritional status and progression of the disease across various types of cancers.</p><p><strong>Material and methods: </strong>Retrospective data from 200 consecutive Caucasian cancer patients admitted to a major oncology hospital for cancer treatment were analyzed according to age, sex, cancer type, nutritional status (percentage body weight loss - %BWL), body mass index (BMI), percentage of dietary intake from the calculated requirement for nutrients (%DI)), and laboratory results (albumin levels, total protein concentration, C-reactive protein - CRP). Inflammatory biomarkers such as prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were assessed.</p><p><strong>Results: </strong>Prognostic nutritional index (ρ = -0.464, <i>p</i> < 0.001), PLR (ρ = 0.293, <i>p</i> = 0.019), albumin level (ρ = -0.490, <i>p</i> < 0.001), platelet count (ρ = 0.114, <i>p</i> = 0.370), neutrophil count (ρ = 0.273, <i>p</i> = 0.030), CRP (ρ = 0.293, <i>p</i> = 0.019) and lymphocyte count (ρ = -0.288, <i>p</i> = 0.021) were significantly associated with %BWL. No significant association was found with NLR. Cancer dissemination was significantly associated with PNI (OR: 0.93, 95% CI: 0.88-0.98), PLR (OR: 1.00, 95% CI: 1.00-1.01), albumin (OR: 0.86, 95% CI: 0.80-0.93), platelet count (OR: 1.01, 95% CI: 1.00-1.01), %BWL (OR: 1.06, 95% CI: 1.02-1.10) and %DI (OR: 0.97, 95% CI: 0.96-0.99) but not with NLR, total protein level, total lymphocyte count, or BMI. For patients with albumin levels below 35 g/l, the likelihood of disseminated cancer was more than five times higher (OR: 5.45, 95% CI: 2.05-14.48).</p><p><strong>Conclusions: </strong>The intensity of inflammation may be responsible for the severity of malnutrition and cancer prognosis.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 1","pages":"45-54"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144044198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of Rosai-Dorfman disease mimicking a malignant lymphoproliferative process and IgG4-related disease.","authors":"Jakub Czerwiński, Mateusz Pysiewicz, Julia Maria Sołek, Aleksandra Opinc, Tadeusz Robak, Joanna Makowska, Marcin Braun","doi":"10.5114/wo.2025.150079","DOIUrl":"10.5114/wo.2025.150079","url":null,"abstract":"<p><p>Rosai-Dorfman disease (RDD), or sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic disorder that often mimics malignancies and immune-mediated conditions such as IgG4-related disease (IgG4-RD). We report a 73-year-old male with a 2-year history of systemic symptoms, including fever, significant weight loss, and generalised lymphadenopathy, accompanied by strikingly elevated IgG4 levels. Advanced imaging revealed metabolically active lesions in lymph nodes, paranasal sinuses, and bones, complicating the differential diagnosis and raising concerns for malignancy or IgG4-RD. Histopathological examination revealed hallmark features of RDD, including S-100 positivity highlighting emperipolesis and negative CD1a staining, leading to the final diagnosis. The patient initially improved with glucocorticosteroids but achieved sustained symptom resolution with methotrexate, underscoring the potential of antimetabolites for systemic RDD. This case exemplifies the diagnostic and therapeutic challenges of RDD, emphasizing the importance of a multidisciplinary approach and further investigation of targeted therapies for complex and systemic presentations.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":"29 2","pages":"206-209"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}